ArticleRespiratory research2026
CB2 receptor agonist JWH133 attenuates hyperoxia-induced acute lung injury by inhibiting ferroptosis via GPX4 upregulation.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundActivation of the cannabinoid type 2 (CB2) receptor has been demonstrated to offer protective effects against various inflammatory conditions and tissue injuries across different organs. Ferroptosis, a form of regulated cell death characterized by iron-dependent lipid peroxidation, has been increasingly recognized as a contributor to the severity of acute lung injury (ALI). However, the precise role of CB2 receptor activation in hyperoxia-induced acute lung injury (HALI) remains poorly defined.
methodsThis study investigated the effects of JWH133, a selective CB2 receptor agonist, using both in vivo animal models and in vitro cellular models exposed to hyperoxia conditions. Lung tissue and bronchoalveolar lavage fluid (BALF) were collected at the end of the experiments for analyses, and animal survival rates were recorded throughout the experimental period. Concurrently, mouse lung epithelial cells (MLE-12) were cultured under hyperoxia conditions. To specifically elucidate the role of GPX4, siRNA-mediated knockdown was employed in both animal and cellular models, providing a detailed assessment of its functional relevance.
resultsTreatment with JWH133 significantly improved survival rates, reduced pulmonary edema, and markedly decreased inflammatory cytokine levels, oxidative stress markers, and indicators of ferroptosis in hyperoxia-exposed models. Furthermore, JWH133 effectively inhibited NF-κB signaling and reduced cell death in lung tissues, accompanied by enhanced expression of glutathione peroxidase 4 (GPX4). Consistent with these in vivo findings, hyperoxia-exposed MLE-12 cells treated with JWH133 exhibited similar protective effects. Notably, the protective effects of JWH133 were negated when GPX4 expression was silenced using targeted siRNA in both animal and cellular models.
conclusionOur findings suggest that JWH133 confers protection against HALI primarily by upregulating GPX4 expression, highlighting its potential as a promising therapeutic strategy for HALI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.